Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Leukemia Clinical Trial

Official title:

Hematopoietic Cell Transplantation in the Treatment of Infant Leukemia and Myelodysplastic Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00357565
• Other study ID #: 2005LS075
• Secondary ID: UMN-MT2005-25UMN
• Status: Recruiting
• Phase: Phase 2
• Start date: November 2005
• Est. completion date: December 2025

Study information

• Verified date: January 2024
• Source: Masonic Cancer Center, University of Minnesota
• Contact: Christen Ebens, MD
• Phone: 612-624-0123
• Email: ebens012[@]umn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Giving chemotherapy, such as busulfan, fludarabine, and melphalan, before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal or cancer cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil may stop this from happening.

PURPOSE: This phase II trial is studying how well combination chemotherapy followed by a donor umbilical cord blood transplant works in treating infants with high-risk acute leukemia or myelodysplastic syndromes.

Description:

OBJECTIVES:

Primary

• Determine the incidence of engraftment, defined as achieving donor-derived neutrophil count > 500/mm³ by day 42, in infants with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes treated with a non-irradiation containing myeloablative conditioning regimen comprising busulfan, fludarabine, and melphalan followed by double umbilical cord blood transplantation (UCBT) with two partially HLA-matched units.

Secondary Objectives

• Determine the incidence of transplant-related mortality (TRM) at 6 months after UCBT

• Evaluate pattern of chimerism after double UCBT

• Determine the incidence of platelet engraftment at 1 year after UCBT

• Determine the incidence of acute graft-versus-host disease (GVHD) grade II-IV and grade III-IV at day 100 after UCBT

• Evaluate the developmental outcome after UCBT

Transplant Related Objectives

• Determine the incidence of chronic GVHD at 1 year after UCBT

• Determine the survival and disease free survival at 1 and 2 years after UCBT

• Determine the incidence relapse at 1 and 2 years after UCBT

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: December 2025
• Est. primary completion date: December 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 3 Years

Eligibility

Inclusion Criteria:

• Matched sibling donor (HLA 8/8), if available, or a unrelated partially HLA matched single unit based on the following priority:

• 1st priority: 4/6 matched unit, cell dose >5 x 10-7 nucleated cells/kg

• 2nd priority: 5/6 matched unit, cell dose > 4 x 10-7 nucleated cells/kg

• 3rd priority: 6/6 matched unit, cell dose > 3 x 10-7 nucleated cells/kg

• Patients aged = 3 years at diagnosis (not age of transplant) with hematological malignancy as detailed below:

• Acute myeloid leukemia: high risk CR1 as evidenced by:

• High risk cytogenetics t(4;11) or other MLL rearrangements; chromosome 5, 7, or 19 abnormalities; complex karyotype (>5 distinct changes); = 2 cycles to obtain complete response (CR); CR2 or higher; Preceding myelodysplastic syndrome (MDS); All patients must be in CR or early relapse (i.e., <15% blasts in BM).

• Acute lymphocytic leukemia: high risk CR1 as evidenced by: High-risk cytogenetic: t(4;11) or other MLL rearrangements; hypodiploid; t(9;22); >1 cycle to obtain CR; CR2 or higher; All patients must be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a cellularity of =15%.

• Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory anemia with severe pancytopenia or high risk cytogenetics. Blasts must be < 10% by a representative bone marrow aspirate morphology.

• Persistent or rising minimal residual disease (MRD) after standard chemotherapy regimens: Patients with evidence of minimal residual disease at the completion of therapy or evidence of rising MRD while on therapy. MRD will be defined by either flow cytometry (>0.1% residual cells in the blast gate with immune phenotype of original leukemic clone), by molecular techniques (PCR or FISH) or conventional cytogenetics (g-banding).

• New Leukemia Subtypes: A major effort in the field of pediatric hematology is to identify patients who are of high risk for treatment failure so that patients can be appropriately stratified to either more (or less) intensive therapy. This effort is continually ongoing and retrospective studies identify new disease features or characteristics that are associated with treatment outcomes. Therefore, if new high risk features are identified after the writing of this protocol, patients can be enrolled with the approval of two members of the study committee.

• Recipients must have a Lansky score = 50% and have acceptable organ function defined as:

• Renal: glomerial filtration rate > 60ml/min/1.73m^2

• Hepatic: bilirubin, AST/ALT, ALP < 5 x upper limit of normal,

• Pulmonary function: oxygen saturation >92%

• Cardiac: left ventricular ejection fraction > 45%.

• Voluntary written informed consent before performance of any study-related procedure not part of normal medical care.

Exclusion Criteria:

• Active infection at time of transplantation (including active infection with Aspergillus or other mold within 30 days).

• History of HIV infection or known positive serology

• Myeloablative transplant within the last 6 months.

• Evidence of active extramedullary disease (including central nervous system leukemia).

Related Conditions & MeSH terms

• Anemia
• Anemia, Refractory, with Excess of Blasts
• Childhood Acute Lymphoblastic Leukemia in Remission
• Childhood Acute Myeloid Leukemia in Remission
• Childhood Myelodysplastic Syndrome
• De Novo Myelodysplastic Syndrome
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Myelodysplastic Syndromes
• Neoplasm Metastasis
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Preleukemia
• Previously Treated Myelodysplastic Syndrome
• Recurrent Childhood Acute Myeloid Leukemia
• Refractory Anemia
• Refractory Anemia With Excess Blasts
• Refractory Anemia With Excess Blasts in Transformation
• Secondary Acute Myeloid Leukemia
• Secondary Myelodysplastic Syndrome
• Syndrome

Intervention

Biological:
• filgrastim
All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.

Drug:
• busulfan
Administered 1.1 mg/kg if <12 kg intravenous (IV) every 6 hours (0.8 mg/kg if >12 kg IV every 6 hours on Days -8 through -5.
• cyclosporine
Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of >200 ng/mL. For children < 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
• fludarabine phosphate
Administered 25 mg/m^2 intravenous (IV) over 60 minutes on Days -4 through -2.
• melphalan
Administered 60 mg/m^2 intravenous (IV) over 30 minutes on Days -4 through -2.
• mycophenolate mofetil
All patients will begin mycophenolate mofetil (MMF) on day -3. Patients <45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).

Procedure:
• umbilical cord blood transplantation
The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.

Locations

Country	Name	City	State
United States	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Engraftment	Defined as achieving donor derived neutrophil count >500/uL by day 42 in young children with leukemia or myelodysplastic syndrome undergoing a partially matched single unit umbilical cord blood transplant (UCBT) after a myeloablative preparative regimen consisting of busulfan, melphalan and fludarabine.	Day 42 After Transplant
Secondary	Incidence of transplant-related mortality (TRM)	defined as death due to transplant	at 6 months after transplant
Secondary	Incidence of platelet engraftment	defined as platelet count > 50,000	at 1 year after transplant
Secondary	Incidence of acute graft-versus-host disease (GVHD) grade II-IV and grade III-IV	Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.	Day 100 After Transplant
Secondary	Incidence of chronic graft-versus-host disease (GVHD)	Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation in which functional immune cells in the transplanted marrow recognize the recipient as "foreign" and mount an immunologic attack.	1 Year After Transplant
Secondary	Incidence of relapse	defined using standard criteria (bone marrow blast count and cytogenetics).	1 and 2 years after transplant
Secondary	Overall survival	Alive after transplant.	at 1 and 2 years after transplant
Secondary	Developmental Outcomes	Neuropsychological evaluation to assess baseline neurocognitive, adaptive, and behavioral functioning and presence of developmental delays	at 1, 2, and 5 years after transplant
Secondary	Disease-free survival	defined as patients who are alive and in hematological remission.	at 1 and 2 years after transplant